[Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
Zhonghua Yi Xue Za Zhi
; 93(2): 96-8, 2013 Jan 08.
Article
em Zh
| MEDLINE
| ID: mdl-23648343
ABSTRACT
OBJECTIVE:
To observe the preliminary efficacies and adverse events of sunitinib in the treatment of metastatic breast cancer ulcer.METHODS:
From December 2008 to May 2010, patients with advanced breast cancer ulcer took a single sunitinib. The dosage was adjusted on the basis of adverse events. And clinical response was evaluated.RESULTS:
Nine patients with advanced breast cancer ulcer finished the treatment. The objective response and the clinical benefit time to progression of sunitinib were 3 and 7 patients with metastatic breast cancer ulcer, and the median time to progression (TTP) was 2.0 months. The most common adverse events included fatigue, hand-foot syndrome, neutropenia, thrombocytopenia and hypertension.CONCLUSION:
Single-agent sunitinib treatment of refractory advanced breast cancer ulcer has marked efficacies. However, neutropenia, thrombocytopenia and hypertension are the major dose-limited toxicities.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Pirróis
/
Úlcera
/
Neoplasias da Mama
/
Indóis
/
Antineoplásicos
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
Zh
Ano de publicação:
2013